- Home
- IBG vs NXL Comparison
IBG vs NXL Comparison
Compare IBG & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBG
- NXL
- Stock Information
- Founded
- IBG 2018
- NXL 2010
- Country
- IBG Australia
- NXL United States
- Employees
- IBG N/A
- NXL N/A
- Industry
- IBG Beverages (Production/Distribution)
- NXL Medical Specialities
- Sector
- IBG Consumer Staples
- NXL Health Care
- Exchange
- IBG Nasdaq
- NXL Nasdaq
- Market Cap
- IBG 9.3M
- NXL 10.0M
- IPO Year
- IBG 2024
- NXL 2022
- Fundamental
- Price
- IBG $1.11
- NXL $3.82
- Analyst Decision
- IBG Strong Buy
- NXL Strong Buy
- Analyst Count
- IBG 1
- NXL 1
- Target Price
- IBG N/A
- NXL $3.00
- AVG Volume (30 Days)
- IBG 1.7M
- NXL 2.0M
- Earning Date
- IBG 01-01-0001
- NXL 11-08-2024
- Dividend Yield
- IBG N/A
- NXL N/A
- EPS Growth
- IBG N/A
- NXL N/A
- EPS
- IBG N/A
- NXL N/A
- Revenue
- IBG $3,147,763.00
- NXL $162,078.00
- Revenue This Year
- IBG N/A
- NXL $51.39
- Revenue Next Year
- IBG N/A
- NXL $177.11
- P/E Ratio
- IBG N/A
- NXL N/A
- Revenue Growth
- IBG N/A
- NXL 26.00
- 52 Week Low
- IBG $0.60
- NXL $0.25
- 52 Week High
- IBG $3.35
- NXL $4.36
- Technical
- Relative Strength Index (RSI)
- IBG N/A
- NXL 64.56
- Support Level
- IBG N/A
- NXL $3.65
- Resistance Level
- IBG N/A
- NXL $4.36
- Average True Range (ATR)
- IBG 0.00
- NXL 0.58
- MACD
- IBG 0.00
- NXL -0.04
- Stochastic Oscillator
- IBG 0.00
- NXL 72.45
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter and retailer of a growing beverage portfolio of 60 formulations across 13 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.